Literature DB >> 33061191

Aortic valve repair in endocarditis: scope and results.

Silvia Solari1, Saadallah Tamer1, Gaby Aphram1, Stefano Mastrobuoni1, Emiliano Navarra1, Philippe Noirhomme1, Alain Poncelet1, Parla Astarci1, Jean Rubay1, Gébrine El Khoury1, Laurent De Kerchove1.   

Abstract

PURPOSE: Infective endocarditis (IE) remains a prevalent and life-threatening disease. The choice to repair or replace the infected valve still remains a matter of debate, especially in aortic valve (AV) infections. We retrospectively analyze our two decades of experience in aortic valve repair (AVr) in IE. Long-term outcomes are described with particular attention to the impact of valve configuration and the use of patch techniques.
METHODS: From September 1998 to June 2017, 42 patients underwent AVr in a single center for IE. Techniques include leaflet patch repair and resuspension and aortic annulus stabilization.
RESULTS: Hospital mortality was 2.4% (n = 1). The median follow-up was 90.6 months. Survival was 89 ± 9.4% and 76.6 ± 16% at 5 and 10 years, respectively, with no significant differences between tricuspid aortic valve (TAV) and bicuspid aortic valve (BAV). Freedom from reoperation was 100% and 92.9 ± 7.1% in TAV and 81.8 ± 18.2% and 46.8 ± 28.8% in BAV at 5 and 10 years, respectively (TAV vs BAV, p = 0.02). BAV, degree of preoperative aortic insufficiency, and AVr including patch were factors predicting a higher risk of reoperation during the follow-up.
CONCLUSION: In our experience, AVr is a safe, feasible, and efficient choice in selected patients with healed or active IE. Durability of the repair is excellent in patients with limited lesions and in patients with TAV even with patch repair. Reoperations occurred principally in patients with BAV and severe preoperative AI, in whom patch repair was performed. In those patients, we actually recommend to replace the valve in case of active endocarditis. © Indian Association of Cardiovascular-Thoracic Surgeons 2019.

Entities:  

Keywords:  Aortic valve repair; Infective endocarditis; Patch repair

Year:  2019        PMID: 33061191      PMCID: PMC7525605          DOI: 10.1007/s12055-019-00831-0

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  25 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Valve sparing-root replacement with the reimplantation technique to increase the durability of bicuspid aortic valve repair.

Authors:  Laurent de Kerchove; Munir Boodhwani; David Glineur; Michel Vandyck; Jean-Louis Vanoverschelde; Philippe Noirhomme; Gebrine El Khoury
Journal:  J Thorac Cardiovasc Surg       Date:  2011-09-28       Impact factor: 5.209

3.  Guidelines for reporting mortality and morbidity after cardiac valve interventions.

Authors:  Cary W Akins; D Craig Miller; Marko I Turina; Nicholas T Kouchoukos; Eugene H Blackstone; Gary L Grunkemeier; Johanna J M Takkenberg; Tirone E David; Eric G Butchart; David H Adams; David M Shahian; Siegfried Hagl; John E Mayer; Bruce W Lytle
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

4.  Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis.

Authors:  M R Moon; D C Miller; K A Moore; P E Oyer; R S Mitchell; R C Robbins; E B Stinson; N E Shumway; B A Reitz
Journal:  Ann Thorac Surg       Date:  2001-04       Impact factor: 4.330

5.  Surgical treatment of active infective endocarditis: a continued challenge.

Authors:  Tirone E David; Gheorghe Gavra; Christopher M Feindel; Tommaso Regesta; Susan Armstrong; Manjula D Maganti
Journal:  J Thorac Cardiovasc Surg       Date:  2006-11-30       Impact factor: 5.209

6.  Long-term results of external aortic ring annuloplasty for aortic valve repair.

Authors:  Emmanuel Lansac; Isabelle Di Centa; Ghassan Sleilaty; Stephanie Lejeune; Nizar Khelil; Alain Berrebi; Christelle Diakov; Leila Mankoubi; Marie-Christine Malergue; Milena Noghin; Konstantinos Zannis; Suzanna Salvi; Patrice Dervanian; Mathieu Debauchez
Journal:  Eur J Cardiothorac Surg       Date:  2016-08       Impact factor: 4.191

7.  Surgical treatment of active native aortic valve endocarditis with allografts and mechanical prostheses.

Authors:  Loes M A Klieverik; Magdi H Yacoub; Sue Edwards; Jos A Bekkers; Jolien W Roos-Hesselink; A Pieter Kappetein; Johanna J M Takkenberg; Ad J J C Bogers
Journal:  Ann Thorac Surg       Date:  2009-12       Impact factor: 4.330

8.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).

Authors:  Gilbert Habib; Patrizio Lancellotti; Manuel J Antunes; Maria Grazia Bongiorni; Jean-Paul Casalta; Francesco Del Zotti; Raluca Dulgheru; Gebrine El Khoury; Paola Anna Erba; Bernard Iung; Jose M Miro; Barbara J Mulder; Edyta Plonska-Gosciniak; Susanna Price; Jolien Roos-Hesselink; Ulrika Snygg-Martin; Franck Thuny; Pilar Tornos Mas; Isidre Vilacosta; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

9.  Outcomes and prosthesis choice for active aortic valve infective endocarditis: analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database.

Authors:  Edward B Savage; Paramita Saha-Chaudhuri; Craig R Asher; J Matthew Brennan; James S Gammie
Journal:  Ann Thorac Surg       Date:  2014-07-29       Impact factor: 4.330

10.  Durability of tissue-engineered bovine pericardium (CardioCel®) for a minimum of 24 months when used for the repair of congenital heart defects.

Authors:  Douglas Bell; Sudesh Prabhu; Kim Betts; Robert Justo; Prem Venugopal; Tom R Karl; Nelson Alphonso
Journal:  Interact Cardiovasc Thorac Surg       Date:  2019-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.